Latest news and upcoming events
Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline
Extension led by Pontifax Venture Capital and existing investors Novo Holdings and Ysios Capital, raising an additional 31M EUR
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
FDA Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis
Lava Therapeutics announces appointment of Christy J. Oliger to its board of directors
Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role
Am-Pharma to present data from phase 3 revival study at upcoming scientific conferences
A significant reduction in major adverse kidney events by day 90 was observed
VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer
Dr. Lawson is a renowned scientist in blood coagulation biochemisty and surgical hemostasis.
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Closed $31.0 million private placement financing, extending cash runway into 1Q 2025
AELIX Therapeutics presents positive results from randomized placebocontrolled phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial
The study achieved its primary and secondary endpoints of safety, tolerability and immunogenicity.
Subscribe to our weekly newsletter for the latest
updates on life sciences investments.